Ads
related to: new heart failure drug approved
Search results
Results From The WOW.Com Content Network
A new paper was published on these findings and MedCo filed for a new patent for the drug as a treatment for heart failure specifically in black patients. [ 4 ] [ 7 ] [ 8 ] The new patent and the old patent were then licensed to a company called NitroMed, which ran a clinical called the African-American Heart Failure Trial (A-HeFT), the results ...
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...
Dapagliflozin was approved for medical use in the United States in January 2014. [66] [36] In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. [11]
(Reuters) -Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according ...
On Wednesday, Windtree Therapeutics, Inc. (NASDAQ:WINT) released topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients in early cardiogenic shock due to heart failure.
Details presented at annual meeting of the American Heart Association (AHA) held virtually this year follow the release in October of initial results for the 8,256-patient trial. The benefit ...
Ads
related to: new heart failure drug approved